Table 4.

Ongoing radio-immunotherapy studies in stage III NSCLC.

NCT Number/Trial Name	Study Phase	Patients	IO Agent	Trial Design	RT Dose	RT and IO Timing	Status
NCT03237377	II Single arm	Resectable Stage IIIA NSCLC	Durvalumab ± tremelimumab	Neoadjuvant IO + RT, followed by surgery	45 Gy/25 fx	Concurrent	Recruiting
NCT04245514	II Single arm with 3 radiotherapy cohorts	Resectable Stage IIIA NSCLC	Durvalumab	Neoadjuvant IO + RT followed by surgery	Allocated in a 1:1:1 ratio: Arm A: 20 × 2 Gy Arm B: 5 × 5 Gy Arm C: 3 × 8 Gy	Concurrent	Recruiting
NCT02987998	I	Resectable Stage IIIA NSCLC	Pembrolizumab	Neoadjuvant chemoRT (cisplatin-etoposide) + IO, followed by surgery, followed by consolidation IO	45 Gy/25 fx	Concurrent	Active, not recruiting
NCT02904954	II Randomised	Resectable Stage I-IIIA NSCLC	Durvalumab	Neoadjuvant IO ± SBRT, followed by surgery, followed by postoperative maintenance IO	SBRT to 24 Gy/3 fx	Concurrent	Active, not recruiting
NCT03871153	II Single arm	Resectables Stage IIIA NSCLC	Durvalumab	Neoadjuvant chemoRT (carboplatin–paclitaxel) + IO followed by surgery	45–61.2 Gy 1.8–2.0 Gy per day		Recruiting

IO = immunotherapy; RT = radiotherapy; NSCLC = non-small-cell lung cancer; Gy = grays; fx = fractions; SBRT = stereotactic body radiation therapy.